Has Subramanya Rao, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,237,613 in general payments to Subramanya Rao, MD across 811 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Subramanya Rao, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Subramanya Rao, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Subramanya Rao, MD

Hematology & Oncology · Tinley Park, ILNPI 1740256783

Payments from drug & device makers

$2,237,613in general payments, 2019–2025

Across 811 payments — averaging $2759.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Beigene, Ltd.$1.3M
Tesaro, Inc.$296K
Novartis$234K
Eisai Inc.$109K
Beone Medicines Ltd.$52K
Radius Health, Inc.$46K
plus $214K from 54 others

$729in research payments, 2019–2025

Across 3 payments — averaging $243.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pharmacyclics LLC, An Abbvie Company$650
Eli Lilly$79

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Beigene, Ltd.	59	$1,286,450
Tesaro, Inc.	12	$295,604
Novartis	43	$233,776
Eisai Inc.	59	$109,253
Beone Medicines Ltd.	1	$52,400
Radius Health, Inc.	3	$46,164
Sanofi US Services Inc.	4	$41,450
Amgen	13	$39,813
GSK	17	$23,971
E.r. Squibb & Sons, L.L.C.	45	$17,986
Daiichi Sankyo Inc.	13	$15,350
Bristol Myers Squibb	23	$13,037
F. Hoffmann-la Roche AG	3	$10,915
Incyte Corporation	26	$8,316
Mirati Therapeutics, Inc.	4	$5,530
Pfizer	49	$5,236
Johnson & Johnson(2 entities)	51	$4,948
Astrazeneca UK Limited	2	$4,706
AstraZeneca(2 entities)	34	$3,104
Epizyme, Inc.	2	$2,903
Stemline Therapeutics Inc.	6	$2,796
Bayer	8	$1,908
Exelixis Inc.	5	$1,607
Pharmacyclics LLC, An Abbvie Company	17	$1,270
Karyopharm Therapeutics Inc.	5	$1,175
Merck	64	$1,144
Adaptive Biotechnologies Corporation	2	$823
ASD Specialty Healthcare, LLC	14	$603
Lilly USA, LLC	21	$529
Genentech USA, Inc.	24	$505
Astellas Pharma US Inc	21	$445
EMD Serono, Inc.	19	$378
Seagen Inc.	18	$361
AbbVie	13	$336
Gilead(2 entities)	17	$318
Takeda Pharmaceuticals U.S.A., Inc.	11	$283
Dova Pharmaceuticals	10	$194
Jazz Pharmaceuticals Inc.	2	$153
Beigene USA, Inc.	3	$146
Rigel Pharmaceuticals, Inc.	4	$132
Array Biopharma Inc	5	$117
Global Blood Therapeutics, Inc.	5	$108
Regeneron Healthcare Solutions, Inc.	1	$94
Blueprint Medicines Corporation	4	$94
Puma Biotechnology, Inc.	1	$86
ADC Therapeutics America, Inc.	1	$84
Sanofi	5	$77
Agios Pharmaceuticals, Inc.	3	$75
Morphosys, US Inc.	3	$74
Taiho Oncology, Inc.	4	$72
Coherus Oncology, Inc.	2	$64
Melinta Therapeutics, LLC	2	$58
Sumitomo Pharma America, Inc.	2	$56
G1 Therapeutics, Inc.	2	$48
Myriad Genetic Laboratories, Inc.	2	$44
Pharmacosmos Therapeutics Inc.	2	$43
Pharmaessentia USA Corporation	2	$37
Cardinal Health 108 LLC	1	$34
Tempus AI, Inc	1	$29
Foundation Medicine, Inc.	2	$29

How this compares

$2,237,613 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024

$132,840

Medicare patients

422

Services billed

1,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Tinley Park

Richard SchilskyBurr Ridge$87.1M
Edwin PosadasBurr Ridge$70.9M
Oana DanciuChicago$23.2M
Shuo MaChicago$20.5M
Olwen HahnChicago$11.9M
Christine BestvinaChicago$11.3M
Russell SzmulewitzChicago$9.8M
Randy SweisChicago$9.4M
Hedy KindlerChicago$8.6M
Reem KarmaliChicago$7.7M

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →